Magnesium citrate tablets
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Oral formulations containing magnesium citrate.
1 to 2 tablets three times a day.
Children aged 12 to 18 years
1 tablet three times a day.
Tablets may be broken in half using the score line to facilitate ease of swallowing, not to divide equal doses.
Children under 12 years
Renal impairment - glomerular filtration rate below 30ml/minute
Precautions and Warnings
Cardiac conduction defects
Correct hypocalcaemia before or during treatment
Advise patient not to take other medicines within 2 hours
Correct hypokalaemia before or during treatment
Monitor serum magnesium regularly
Interrupt or reduce dose if diarrhoea occurs
Bioavailability differs with preparations;caution on changing formulations
Monitor serum magnesium levels every 3 to 6 months, particularly in children and patients with renal impairment.
Patients who struggle to swallow tablets should be treated with a magnesium powder for oral solution.
Diabetes mellitus, hyperthyroidism and hyperaldosteronism are linked with hypomagnesaemia, these conditions should be considered and excluded.
Magnesium citrate is not intended for first-line treatment for patients with severe symptomatic hypomagnesaemia or serum levels less than 0.4mmol/L. Treatment may begin when serum magnesium rises above 0.4mmol/L or when acute symptoms of hypomagnesaemia have resolved.
Pregnancy and Lactation
Magnesium citrate is considered safe for use during pregnancy.
The manufacturer advises magnesium citrate may be used during pregnancy if clinically needed. Available reports indicate no risk of teratogenic or developmental effects.
Magnesium citrate is considered safe for use during breastfeeding.
The manufacturer states magnesium citrate may be used safely when breastfeeding. Whilst available data indicates magnesium citrate is present in human breast milk, the quantity is not considered to be sufficient to cause adverse effects in the breastfed infant.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet (https://www.toxbase.org/).
Last Full Review Date: June 2021
Summary of Product Characteristics: Magnesium Kora Healthcare 4mmol (97mg) tablets. Kora Corporation Ltd t/a Kora Healthcare. Revised February 2021.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.